Occurrence of adverse events among patients with inflammatory bowel disease in the HealthCore Integrated Research Database
Megan McAuliffe(Takeda (Japan)), Irving H. Fox(Takeda (United States)), Daina B. Esposito(Andover Eye Associates), Crystal N. Holick(Fred Hutch Cancer Center), Jane Porter(Takeda (Japan)), Gerald A. Faich(United BioSource Corporation (United Kingdom)), Asit Parikh, Stephan Lanes(Boehringer Ingelheim (United States)), Timothy Leach(Takeda (United States)), Yueqin Zhao(United States Food and Drug Administration)
Cited by 42
Related Papers
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed
|Gastroenterology|2014|714
Treatment of Ulcerative Colitis with a Humanized Antibody to the α <sub>4</sub> β <sub>7</sub> Integrin
|New England Journal of Medicine|2005|694